Success in the biopharmaceutical start-up world is bound to be imitated. But it isn’t often that the imitation is a carbon copy of the original, as is seemingly the case with SV Life Sciences, HBM BioVentures and Novo AS’ new venture Ophthotech Corp.
Ophthotech Raises $36 million, In-licenses Aptamers
Three venture capital firms funded the ophthalmology start-up with a $36 million Series A that will pay for the acquisition of two IND-stage drug candidates: the similarity to another start-up, Lux Biosciences, is startling. Can the founders of Eyetech take the Lux model and build another success for SVLS, HBM Bioventures, and Novo AS?
More from Strategy
• By
Aldeyra’s dry eye candidate reproxalap received a second FDA complete response letter, but the firm expressed confidence about refiling quickly based on two ongoing studies.
• By
The challenging US biosimilar market remains a persistent problem, leading the biosimilar developer to reconsider how it invests in the future while pushing for changes.
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.
• By
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
More from Business
• By
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.